secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001193125-21-228185
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology appoints Helen Collins, M.D. as Class II director
---------------------------------------------------------------

- Appointed effective July 28, 2021; term expires at 2022 annual meeting.
- Previously EVP and CMO at Five Prime Therapeutics, led bemarituzumab development until Amgen acquisition in April 2021.
- Received options for 46,000 shares (3-year vest) and 19,166 shares (1-year vest); annual cash retainer $40,000.
- Annual automatic option grants of 23,000 shares on each annual meeting date, vesting over one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/0001193125-21-228185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/d200489d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-228185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer